The slower growth is due to lower shipments of genome sequencing equipment NovaSeq y-o-y, Illumina guided.
SINGAPORE (Jan 15): Venture Corp’s performance this year could be dragged by a disappointing FY20 revenue guidance by US biotechnology equipment manufacturer Illumina – its major customer – according to CGS-CIMB Research.
CGS-CIMB notes that Illumina’s CEO recently guided that the latter’s revenue could grow 9% to 11% y-o-y, which is below analysts’ expectation of 12%.
